Compare Stocks: INDP, INBX, NKTR, and OMER

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INBX Inhibrx Biosciences	$92.76 -0.6%	$103.74	$28.16 ▼ $155.29	$1.37B	3.81	315,441 shs	208,037 shs
INDP Indaptus Therapeutics	$2.37 +4.9%	$1.97	$0.92 ▼ $5.96	$315.78M	0.97	626,594 shs	506,908 shs
NKTR Nektar Therapeutics	$40.80 +1.3%	$67.74	$33.40 ▼ $109.00	$1.39B	1.26	1.10 million shs	1.75 million shs
OMER Omeros	$19.12 +2.0%	$17.70	$4.05 ▼ $21.24	$1.38B	2.57	1.67 million shs	899,917 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INBX Inhibrx Biosciences	-0.05%	-6.71%	-22.95%	-10.10%	+178.69%
INDP Indaptus Therapeutics	-12.74%	-1.74%	+85.25%	-9.60%	-38.75%
NKTR Nektar Therapeutics	+0.88%	-33.50%	-45.73%	-44.79%	-30.59%
OMER Omeros	+1.30%	-1.52%	-1.06%	+82.57%	+322.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INBX Inhibrx Biosciences	$92.76 -0.6%	$103.74	$28.16 ▼ $155.29	$1.37B	3.81	315,441 shs	208,037 shs
INDP Indaptus Therapeutics	$2.37 +4.9%	$1.97	$0.92 ▼ $5.96	$315.78M	0.97	626,594 shs	506,908 shs
NKTR Nektar Therapeutics	$40.80 +1.3%	$67.74	$33.40 ▼ $109.00	$1.39B	1.26	1.10 million shs	1.75 million shs
OMER Omeros	$19.12 +2.0%	$17.70	$4.05 ▼ $21.24	$1.38B	2.57	1.67 million shs	899,917 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INBX Inhibrx Biosciences	-0.05%	-6.71%	-22.95%	-10.10%	+178.69%
INDP Indaptus Therapeutics	-12.74%	-1.74%	+85.25%	-9.60%	-38.75%
NKTR Nektar Therapeutics	+0.88%	-33.50%	-45.73%	-44.79%	-30.59%
OMER Omeros	+1.30%	-1.52%	-1.06%	+82.57%	+322.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INBX Inhibrx Biosciences	2.50	Moderate Buy	$197.50	112.92% Upside
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
NKTR Nektar Therapeutics	2.77	Moderate Buy	$138.50	239.46% Upside
OMER Omeros	2.71	Moderate Buy	$34.00	77.82% Upside

Current Analyst Ratings Breakdown

Latest INDP, INBX, NKTR, and OMER Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$185.00
9/25/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/23/2026	NKTR Nektar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $50.00
9/22/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/22/2026	OMER Omeros	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$22.00
9/18/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/16/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/11/2026	INBX Inhibrx Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/3/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/28/2026	NKTR Nektar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INBX Inhibrx Biosciences	$1.30M	1,050.33	N/A	N/A	$0.55 per share	168.65
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
NKTR Nektar Therapeutics	$55.23M	25.22	N/A	N/A	$4.41 per share	9.25
OMER Omeros	N/A	N/A	$1.93 per share	9.89	($1.71) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	11/13/2026 (Estimated)
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	14.94	15.80	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)

Latest INDP, INBX, NKTR, and OMER Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	NKTR Nektar Therapeutics	-$2.10	N/A	N/A	N/A	$10.26 million	N/A
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/12/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INBX Inhibrx Biosciences	N/A	5.07	5.07
INDP Indaptus Therapeutics	N/A	19.49	19.49
NKTR Nektar Therapeutics	N/A	10.42	10.42
OMER Omeros	N/A	1.95	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INBX Inhibrx Biosciences	82.46%
INDP Indaptus Therapeutics	7.06%
NKTR Nektar Therapeutics	75.88%
OMER Omeros	48.79%

Insider Ownership

Company	Insider Ownership
INBX Inhibrx Biosciences	18.26%
INDP Indaptus Therapeutics	9.94%
NKTR Nektar Therapeutics	2.50%
OMER Omeros	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INBX Inhibrx Biosciences	110	14.72 million	12.03 million	Optionable
INDP Indaptus Therapeutics	5	133.24 million	120.00 million	Not Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
OMER Omeros	175	72.39 million	64.79 million	Optionable

INDP, INBX, NKTR, and OMER Headlines

Recent News About These Companies

Cantor Fitzgerald upgraded Omeros to Overweight for Omeros stock

1 hour ago | ad-hoc-news.deA

Omeros Corporation (NASDAQ:OMER) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 4, 2026 | americanbankingnews.com

Omeros Corporation (NASDAQ:OMER) Stock Has Consensus Target Price of $34.00

October 4, 2026 | marketbeat.com

Omeros consensus price target cut by 16.67% to $37.40

October 3, 2026 | msn.com

Inside the bitter father-son feud that unravelled the Omeros Bros seafood dynasty - as the tax office winds up the iconic Gold Coast eatery

October 2, 2026 | dailymail.comD

‘Devastated’ Omeros Bros patriarch disowns children as iconic Gold Coast restaurant collapses

October 1, 2026 | themercury.com.auT

Bank of America Corp DE Acquires 194,140 Shares of Omeros Corporation $OMER

October 1, 2026 | marketbeat.com

Omeros Corporation $OMER Shares Sold by Corient Private Wealth LP

September 29, 2026 | marketbeat.com

Omeros Corporation stock falls 3.28 percent while analysts target USD 22.00

September 28, 2026 | ad-hoc-news.deA

Omeros Corporation $OMER Shares Purchased by State Street Corp

September 26, 2026 | marketbeat.com

Omeros stock slips 1.47 percent after Cantor upgrade

September 25, 2026 | ad-hoc-news.deA

Il VP finanziario di Omeros David Borges vende azioni per $419.000

September 25, 2026 | it.investing.com

Omeros (NASDAQ:OMER) Stock: Insider David Borges Sells 10,000 Shares

September 25, 2026 | insidertrades.com

Omeros (NASDAQ:OMER) CAO Sells 10,000 Shares of Company Stock

September 24, 2026 | marketbeat.com

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

September 23, 2026 | finance.yahoo.com

Cantor Fitzgerald upgrades Omeros to overweight from neutral

September 23, 2026 | msn.com

Omeros Corporation stock hits 52-week high at 19.75 USD

September 22, 2026 | uk.investing.com

Omeros Shares Rise After Cantor Fitzgerald Upgrade

September 22, 2026 | finance.yahoo.com

Omeros upgraded at Cantor on Yartemlea opportunity

September 22, 2026 | seekingalpha.com

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

September 22, 2026 | benzinga.com

Omeros (NASDAQ:OMER) Reaches New 12-Month High - Here's What Happened

September 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INDP, INBX, NKTR, and OMER Company Descriptions

Inhibrx Biosciences NASDAQ:INBX

$92.76 -0.60 (-0.64%)

Closing price 04:00 PM Eastern

Extended Trading

$92.86 +0.10 (+0.11%)

As of 07:30 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Indaptus Therapeutics NASDAQ:INDP

$2.37 +0.11 (+4.87%)

Closing price 04:00 PM Eastern

Extended Trading

$2.34 -0.03 (-1.22%)

As of 07:41 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Nektar Therapeutics NASDAQ:NKTR

$40.80 +0.54 (+1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$41.23 +0.43 (+1.06%)

As of 07:39 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Omeros NASDAQ:OMER

$19.12 +0.37 (+1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$19.13 +0.01 (+0.07%)

As of 07:30 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INDP, INBX, NKTR, and OMER Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INDP, INBX, NKTR, and OMER Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INDP, INBX, NKTR, and OMER Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INDP, INBX, NKTR, and OMER Company Descriptions

Inhibrx Biosciences NASDAQ:INBX

Indaptus Therapeutics NASDAQ:INDP

Nektar Therapeutics NASDAQ:NKTR

Omeros NASDAQ:OMER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INDP, INBX, NKTR, and OMER Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INDP, INBX, NKTR, and OMER Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INDP, INBX, NKTR, and OMER Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INDP, INBX, NKTR, and OMER Company Descriptions

Inhibrx Biosciences NASDAQ:INBX

Indaptus Therapeutics NASDAQ:INDP

Nektar Therapeutics NASDAQ:NKTR

Omeros NASDAQ:OMER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools